Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Twelve-week, Randomized, Double-blind, Multi-center, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Aliskiren 150 mg When Added to Standard Therapy in Hypertensive Patients With Stable Heart Failure

NCT00219011 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00219011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Twelve-week, Randomized, Double-blind, Multi-center, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Aliskiren 150 mg When Added to Standard Therapy in Hypertensive Patients With Stable Heart Failure
Lead sponsor
Novartis
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
February 28, 2007
Enrollment
280
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure